Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with enzalutamide in patients with metastatic prostate cancer

Authors
Category Primary study
JournalMolecular Cancer Therapeutics
Year 2021
This article has no abstract
Epistemonikos ID: 5a82aee31668161cdafc052552918a9e1199add5
First added on: Feb 14, 2025